DATA CONSOLE / BPC-157 + TB-500 RECORDS
BPC-157 TB-500 is a two-peptide research blend tracked against the human and preclinical evidence.
Two distinct molecules, two non-overlapping mechanisms, one claimed-but-unproven join. Every constituent finding is logged to its study; the combination row reads NO-HUMAN-DATA.
What the BPC-157 TB-500 record actually contains
BPC-157 TB-500 is not one chemical entity. It is a research-community pairing of two synthetic peptides sold and discussed together as a tissue-repair "stack." Record 01 is BPC-157 (Body Protection Compound 157), a 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV, molecular weight ~1419.5 Da, derived from a protein found in human gastric juice. Record 02 is TB-500, a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, molecular weight ~889.0 Da, corresponding to the actin-binding region (residues 17-23) of the 43-residue protein Thymosin Beta-4.
The two are paired on a single premise: complementary mechanisms. BPC-157 supplies a local cytoprotective and pro-angiogenic signal; TB-500 supplies an intracellular actin-sequestration signal that regulates cell migration [4]. That is the entire rationale for the blend. The data behind each constituent is real but overwhelmingly preclinical, and the data behind the combination does not exist: no controlled clinical trial of BPC-157 with TB-500 has been published for any indication, and no peer-reviewed study defines a synergy dose, ratio, or endpoint for the two given together [5].
This site reads the blend the way a data console reads two records: each finding tagged to the constituent it belongs to, each datum carrying a verification status — VERIFIED for a citation-confirmed single-compound result, PRECLINICAL for rodent-only or in-vitro work, EXTRAPOLATED for the theoretical synergy claim, and NO-HUMAN-DATA for the blend-level gaps. The BPC-157 TB-500 benefits in the literature are summarized one record at a time, with the join marked honestly. For the human research evidence constituent by constituent, the research dosing context for each peptide, and short answers in the frequently asked questions, follow the links across the console. Nothing here is dispensed, prescribed, or sold.
BPC-157 and TB-500: the two peptides in the Wolverine blend
BPC-157 and TB-500 sit on different sides of the cell. BPC-157 acts mainly extracellularly: it up-regulates VEGFR2, drives the downstream VEGFR2-Akt-eNOS angiogenic pathway, modulates the nitric-oxide system, and sensitizes growth-hormone-receptor signaling in tendon fibroblasts [2]. Its flagship preclinical result is tendon repair — in a fully transected rat Achilles model, 10 microg/kg improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, and in vitro the same compound reversed 4-hydroxynonenal-induced growth inhibition of tendocytes into stimulation [1].
TB-500 acts on the intracellular cytoskeleton. Its LKKTETQ motif binds monomeric G-actin in a 1:1 complex and sequesters it by capping both ends, preventing polymerization — a structure established at 2-angstrom resolution by crystallography of a gelsolin-domain-1-Thymosin-Beta-4 hybrid bound to actin [3]. Regulating that actin pool is what governs cell migration, re-epithelialization, and progenitor mobilization [4].
A caveat travels with the second record. "TB-500" as sold is the 7-mer Ac-LKKTETQ, but the overwhelming majority of efficacy data attributed to it were generated with FULL-LENGTH Thymosin Beta-4 (~4963 Da), not the fragment [4]. The blend inherits this gap — it leans on full-length-protein data for one of its two components. See the combination rationale and synergy claim for how the two records are argued to fit together, and why that argument is an extrapolation rather than a finding.
BPC 157 TB 500: naming, spelling, and the 'Wolverine' stack
The blend is searched under several spellings. "BPC-157 TB-500," "BPC 157 TB 500" (unhyphenated), "BPC157 TB500," and "the BPC-157 TB-500 stack" all point to the same two-peptide pairing. The popular name is "Wolverine" — a research-community label borrowed for the rapid-healing connotation, not an approved product name, not a single registered substance, and not a manufacturer's brand.
That naming matters because the marketing implies more unity than the chemistry supports. There is no standardized composition. Commercial "Wolverine" vials are commonly labeled with a combined per-vial mass — for example ~10 mg BPC-157 plus ~10 mg TB-500 — but no peer-reviewed combination study validates that ratio, and material distributed through non-regulated channels has unverified identity, purity, and actual BPC-157:TB-500 ratio. The name is a convenience; the two records underneath stay distinct.
The BPC-157 TB-500 stack: what is verified, thin, and absent
Read as a status register, the blend's evidence sorts into three states. VERIFIED, single-compound: BPC-157 accelerated transected-Achilles healing in rats [1] and is pro-angiogenic via VEGFR2 [2]; Thymosin Beta-4 sequesters G-actin [3] and carries a broad regenerative mechanism [4]. THIN, human: BPC-157 has only three small pilot studies, and the only completed human safety/PK data in the "TB-500" lineage are for full-length Thymosin Beta-4 — a Phase 1 study in 40 volunteers [5] and a 2021 first-in-human study in 84 volunteers [6] — not the heptapeptide. ABSENT, combination: zero controlled trials of the two together, and no defined synergy dose, ratio, or endpoint [9].
Recent reviews bound the picture honestly. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies (35 preclinical, one human), found "no clinical safety data," rated the evidence level IV-V — the lowest tiers — and made no mention of TB-500 or any combination [7]. A 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides concluded that many unapproved peptides show favorable animal-model repair but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [8]. For where that leaves access — including the Wolverine legal status and 503A compounding picture and the FDA and WADA status of both constituents — see the regulatory record; for the underlying studies, the full reference list.